Metabasis Therapeutics, Inc. and Sankyo Co. Ltd have announced that the development of CS 917 will resume.

&NA;

Open source

DOI: 10.2165/00128415-200510620-00007
Published: 2005-07
Container: Reactions Weekly
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2165/00128415-200510620-00007,
  title = {Metabasis Therapeutics, Inc. and Sankyo Co. Ltd have announced that the development of CS 917 will resume.},
  author = {\&NA;},
  year = {2005},
  journal = {Reactions Weekly},
  doi = {10.2165/00128415-200510620-00007},
  url = {https://doi.org/10.2165/00128415-200510620-00007}
}

RIS

TY  - JOUR
TI  - Metabasis Therapeutics, Inc. and Sankyo Co. Ltd have announced that the development of CS 917 will resume.
AU  - &NA;
PY  - 2005
JO  - Reactions Weekly
DO  - 10.2165/00128415-200510620-00007
UR  - https://doi.org/10.2165/00128415-200510620-00007
ER  -

APA

&NA; (2005). Metabasis Therapeutics, Inc. and Sankyo Co. Ltd have announced that the development of CS 917 will resume.. Reactions Weekly. https://doi.org/10.2165/00128415-200510620-00007

Source records

crossref · retrieved 2026-09-26T03:04:40.987Z